GenomeDx Announces Results From New Validation Study for Decipher Prostate Cancer Classifier

GenomeDx Announces Results From New Validation Study for Decipher Prostate Cancer Classifier
GenomeDx Biosciences has announced its data presented at the 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO) shows significant evidence of the capacity of the Decipher® Prostate Cancer Classifier to predict which patients may benefit from radiotherapy after prostate surgery. The Decipher® Prostate Cancer Classifier is an experimental device that by assessing the activity

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *